Abstract

Ticagrelor is an oral antiplatelet aggregation drug that can reversibly bind platelet P2Y12 receptor.It is mainly metabolized by CYP3A4 and rapidly provides plasma concentration-dependent platelet inhibition after administration.Unlike other P2Y12 receptor antagonists, many clinical features of Ticagrelor are independent of P2Y12 receptor antagonism.Large numbers of studies have shown that Ticagrelor can inhibit adenosine transporter ENT1, and then inhibit intracellular adenosine uptake, increase adenosine half-life and plasma concentration levels, and enhance adenosine-mediated biological effects.This article reviewed the clinical effects of Ticagrelor in inhibiting adenosine uptake and its clinical significance. Key words: Ticagrelor; Adenosine

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.